Dupilumab's growth is driven by its established market presence, new indications like COPD, broad multi-indication use, and strong clinical performance. Recent approvals and phase III trial successes, ...

Genuine Parts (GPC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term ...

Clallam County reports four instances just this week ...